Literature DB >> 26547470

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure.

Lauren B Cooper1, Bradley G Hammill1, Eric D Peterson1, Bertram Pitt2, Matthew L Maciejewski3, Lesley H Curtis1, Adrian F Hernandez1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26547470      PMCID： PMC4843996          DOI： 10.1001/jama.2015.11904

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

3.  Spironolactone use and renal toxicity: population based longitudinal analysis.

Authors:  Li Wei; Allan D Struthers; Tom Fahey; Alexander D Watson; Thomas M Macdonald
Journal:  BMJ       Date:  2010-05-18

4.  Prevalence of multiple chronic conditions in the United States' Medicare population.

Authors:  Kathleen M Schneider; Brian E O'Donnell; Debbie Dean
Journal:  Health Qual Life Outcomes       Date:  2009-09-08       Impact factor: 3.186

5.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

6.  Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.

Authors:  Adrian F Hernandez; Xiaojuan Mi; Bradley G Hammill; Stephen C Hammill; Paul A Heidenreich; Frederick A Masoudi; Laura G Qualls; Eric D Peterson; Gregg C Fonarow; Lesley H Curtis
Journal:  JAMA       Date:  2012-11-28       Impact factor: 56.272
  6 in total
  17 in total

1.  Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.

Authors:  Stephen J Greene; G Michael Felker; Anna Giczewska; Andreas P Kalogeropoulos; Andrew P Ambrosy; Hrishikesh Chakraborty; Adam D DeVore; Marat Fudim; Steven E McNulty; Robert J Mentz; Muthiah Vaduganathan; Adrian F Hernandez; Javed Butler
Journal:  Can J Cardiol       Date:  2019-02-07       Impact factor: 5.223

2.  Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.

Authors:  Lauren B Cooper; Bradley G Hammill; Eric D Peterson; Bertram Pitt; Matthew L Maciejewski; Lesley H Curtis; Adrian F Hernandez
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-01

3.  Development and Validation of a Deep-Learning Model to Screen for Hyperkalemia From the Electrocardiogram.

Authors:  Conner D Galloway; Alexander V Valys; Jacqueline B Shreibati; Daniel L Treiman; Frank L Petterson; Vivek P Gundotra; David E Albert; Zachi I Attia; Rickey E Carter; Samuel J Asirvatham; Michael J Ackerman; Peter A Noseworthy; John J Dillon; Paul A Friedman
Journal:  JAMA Cardiol       Date:  2019-05-01       Impact factor: 14.676

4.  A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure.

Authors:  Erik Nilsson; Pietro De Deco; Marco Trevisan; Rino Bellocco; Bengt Lindholm; Lars H Lund; Josef Coresh; Juan J Carrero
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2018-10-01

5.  Noninvasive Screening Tool for Hyperkalemia Using a Single-Lead Electrocardiogram and Deep Learning: Development and Usability Study.

Authors:  Erdenebayar Urtnasan; Jung Hun Lee; Byungjin Moon; Hee Young Lee; Kyuhee Lee; Hyun Youk
Journal:  JMIR Med Inform       Date:  2022-06-03

6.  Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants.

Authors:  Geoffrey D Barnes; Brahmajee K Nallamothu; Anne E Sales; James B Froehlich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-03-01

7.  Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease.

Authors:  Bertram Pitt; Patrick Rossignol
Journal:  J Am Heart Assoc       Date:  2017-12-23       Impact factor: 5.501

8.  Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.

Authors:  Lauren B Cooper; Steven J Lippmann; Melissa A Greiner; Abhinav Sharma; Jacob P Kelly; Gregg C Fonarow; Clyde W Yancy; Paul A Heidenreich; Adrian F Hernandez
Journal:  J Am Heart Assoc       Date:  2017-12-23       Impact factor: 5.501

9.  Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin-angiotensin system blockers: a UK primary care cohort study.

Authors:  Sarah-Jo Sinnott; Kathryn E Mansfield; Morten Schmidt; Krishnan Bhaskaran; Liam Smeeth; Dorothea Nitsch; Laurie A Tomlinson
Journal:  BMJ Open       Date:  2017-11-16       Impact factor: 2.692

10.  Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study.

Authors:  Sandra Wagner; Marie Metzger; Martin Flamant; Pascal Houillier; Jean-Philippe Haymann; François Vrtovsnik; Eric Thervet; Jean-Jacques Boffa; Ziad A Massy; Bénédicte Stengel; Patrick Rossignol
Journal:  BMC Nephrol       Date:  2017-09-12       Impact factor: 2.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.